2. Disease Areas
  3. Inflammation or Immune System Disease Respiratory Disease
  4. Respiratory Inflammation Lower Respiratory Inflammation
  5. Asthma

Asthma

Asthma is a chronic inflammatory disorder of the airways characterized by recurrent episodes of wheezing, coughing, chest tightness, and shortness of breath, caused by bronchial hyperresponsiveness and variable airflow obstruction. It commonly affects children and young adults, with over 25 million cases in the United States, and results from complex interactions between genetic predisposition and environmental triggers such as allergens and pollutants. Symptoms are often reversible with treatment, and effective management involves identifying warning signs, avoiding triggers, and adhering to medical recommendations.

References:

Asthma (47):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-N0732
    Jolkinolide B 37905-08-1 99.65%
    Jolkinolide B is a bioactive diterpene isolated from the roots of Euphorbia fischeriana Steud with oral activity. Jolkinolide B downregulates XIAP, cIAP1, cIAP2, and phosphorylated Akt, upregulates Smac, activates caspase-3 and caspase-9, and inhibits NF-κB, TGFβ/smad3 and JAK/STAT3 pathways. Jolkinolide B exerts comprehensive biological effects including inducing cancer cell apoptosis, suppressing inflammatory responses, improving lung function, alleviating hepatic steatosis and eliminating intracellular Mycobacterium tuberculosis. Jolkinolide B can be used for the research of leukemia, histiocytic lymphoma, asthma, metabolic dysfunction-associated steatotic liver disease and tuberculosis.
    Jolkinolide B
  • HY-N3519
    Platycodin D3 67884-03-1 98.91%
    Platycodin D3 is a triterpenoid saponin that can be found in Platycodon grandiflorum. Platycodin D3 exhibits multiple activities including anti-inflammation, regulation of airway mucus secretion, improvement of asthmatic airway inflammation and remodeling, and inhibition of hepatitis C virus (HCV) replication. The IC50 value of Platycodin D3 against HCV NS5B RNA-dependent RNA polymerase is 8 μg/mL. Platycodin D3 can be used in studies related to asthma, hepatitis C virus infection and inflammatory diseases.
    Platycodin D3
  • HY-P990090
    Rademikibart 2648260-80-2 99.13%
    Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a KD of 20.7 pM when binding to human IL-4Rα epitopes. Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma.
    Rademikibart
  • HY-135490
    Reproterol 54063-54-6 98.94%
    Reproterol is a selective β2-adrenoceptor agonist and cAMP phosphodiesterase (PDE) inhibitor. Reproterol inhibits adenylate cyclase-induced phosphodiesterase activity. Reproterol inhibits histamine release from mast cells. Reproterol is applicable to research related to asthma.
    Reproterol
  • HY-133159
    Resolvin E2 865532-70-3 98.5%
    Resolvin E2 ((-)-Resolvin E2) is an endogenous lipid mediator produced from eicosapentaenoic acid (EPA) under the catalysis of 5-lipoxygenase (5-LOX), and its production increases in hypoxic environments. Resolvin E2 antagonizes BLT1, partially activates ChemR23, and promotes ubiquitin-proteasome-mediated degradation of COX-2. Resolvin E2 reduces the production of prostaglandin E2, blocks polymorphonuclear leukocyte infiltration, and promotes the resolution of airway inflammation. Resolvin E2 ameliorates lipopolysaccharide (LPS) (HY-D1056)-induced depressive-like behaviors. Resolvin E2 can be used in research related to depression, murine peritonitis, neonatal asthma, and other conditions.
    Resolvin E2
  • HY-P992034
    APG808
    APG808 (PR001) is an anti-human IL-4Rα monoclonal antibody. APG808 binds to IL-4Rα, prevents IL-13Rα1/IL-4Rα heterodimer formation, and disrupts IL-13 and IL-4 mediated signaling. APG808 ablates Fc and complement effector functions. APG808 can be used for the research of chronic obstructive pulmonary disease, asthma, atopic dermatitis.
    APG808
  • HY-116796
    KDM4C-IN-2 23705-85-3
    KDM4C-IN-2 is a histone lysine demethylase KDM4C (JMJD2C) inhibitor with an IC50 of 147 μM and a Ki of 51 μM. KDM4C-IN-2 can be used for the research of cancer, such as prostate and breast cancer.
    KDM4C-IN-2
  • HY-180419
    SF-3-030 1883721-73-0
    SF-3-030 is a potent, selective and non-ATP competitive ERK1/2 inhibitor. SF-3-030 selectively induces apoptosis in melanoma cells containing mutated BRaf and constitutively active ERK1/2 signalling. SF-3-030 mitigates multiple features of asthma in a murine model of asthma. SF-3-030 can be used for the research of asthma and melanomasup.
    SF-3-030
  • HY-114495
    Caerulomycin A 21802-37-9 98.0%
    Caerulomycin A is an orally active immunomodulator and antimicrobial agent. Caerulomycin A targets Smad3, STAT1 and GATA-3. Caerulomycin A downregulates GATA-3 expression, inhibits Th2 cell differentiation and Th2 cytokine production, reduces IgE levels, and alleviates pulmonary inflammatory responses and eosinophil infiltration. Caerulomycin A ameliorates collagen-induced arthritis symptoms, reduces joint inflammation and synovitis, and decreases the levels of proinflammatory cytokines in joints. Caerulomycin A inhibits the growth of some filamentous fungi, yeasts and specific bacteria. Caerulomycin A can be used in research related to arthritis and asthma.
    Caerulomycin A
  • HY-18706
    trans-Tranilast 70806-55-2 99.63%
    trans-Tranilast (trans-MK-341) is an isomer of Tranilast (HY-B0195), and an anti-allergy agent used in studies of bronchial asthma, allergic rhinitis, and atopic dermatitis.
    trans-Tranilast
  • HY-P1111
    Lyn peptide inhibitor 222018-18-0 99.35%
    Lyn peptide inhibitor (YGYRLRRKWEEKIPNP-NH2) is a potent, cell-permeable Lyn kinase inhibitor that inhibits Lyn-coupled signaling pathways associated with the IL-5 receptor while preserving the integrity of other signals. Lyn peptide inhibitor blocks the activation of Lyn and inhibits the binding of Lyn tyrosine kinase to the βc subunit of the IL-3/GM-CSF/IL-5 receptor. Lyn peptide inhibitor can be used in the research of eosinophilic diseases such as asthma and allergy.
    Lyn peptide inhibitor
  • HY-P99417
    Abrezekimab 2043952-59-4
    Abrezekimab (UCB4144; VR 942) is a humanized, high-affinity, neutralizing anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents IL-13 binding to the IL-13 Rα1 subunit. Abrezekimab can be used for the research of asthma.
    Abrezekimab
  • HY-P991278
    ABM-125
    ABM-125 is a IL-25 neutralizer and immune response modulator. ABM-125 neutralizes human and mouse IL-25 and blocks type 2 immune activation function. ABM-125 regulates virus-induced inflammatory cytokine expression and increases the expression level of antiviral interferons in rhinovirus-infected asthmatic bronchial epithelial cells. For the isotype control of ABM-125, refer to Human IgG1 kappa, Isotype Control (HY-P99001). ABM-125 is applicable to research related to virus-induced acute asthma exacerbations.
    ABM-125
  • HY-159536
    Frevecitinib 1299417-07-4 99.42%
    Frevecitinib (KN-002) is a potent pan-JAK inhibitor (i.e. JAK1, JAK2, JAK3, TYK2). Frevecitinib can be used for the study of asthma and other respiratory conditions such as chronic obstructive pulmonary disease (COPD).
    Frevecitinib
  • HY-163101
    CP-96021 139401-43-7 98.04%
    CP-96021 is an orally active dual leukotriene D4 (LTD4) and platelet activating factor (PAF) receptor antagonist, featuring a guinea pig LTD4 receptor Ki of 34 nM and a rabbit PAF receptor Ki of 37 nM. CP-96021 blocks ligand binding to its target receptors, inhibits ligand-induced bronchoconstriction, and inhibits antigen-triggered airway obstructive effects. CP-96021 can be used for the research of asthma.
    CP-96021
  • HY-101427
    Bamaquimast 135779-82-7 98.97%
    Bamaquimast (F 10126) is an anti-asthmatic agent and mediator release inhibitor. Bamaquimast can be used in the research of chronic obstructive bronchopulmonary disease.
    Bamaquimast
  • HY-P992447
    QX008N
    QX008N is a humanized IgG1 monoclonal antibody and also a TSLP inhibitor with a KD value of 0.0175 nM. QX008N blocks TSLP-induced signaling pathways by inhibiting the interaction of TSLP-TSLPR-IL-7Rα. QX008N reduces eosinophil and IgE levels, improves pulmonary function, blocks TSLP-induced inflammation, and enhances the inhibitory effect on inflammatory mediators when administered in combination with anti-IL-4R antibodies. QX008N is applicable to relevant research on asthma.
    QX008N
  • HY-182625
    GS-1160-180 111878-47-8
    GS-1160-180 is a PAF receptor antagonist. GS-1160-180 competes with PAF for receptor binding, with no activity against collagen or adenosine diphosphate-induced platelet aggregation. GS-1160-180 can be used for research on asthma, anaphylactic shock, gastric ulceration, and transplant rejection.
    GS-1160-180
  • HY-P992150
    Altrakincept
    Altrakincept is a recombinant hIL-4 receptor and IL-4 neutralizer. Altrakincept neutralizes endogenous IL-4, and prevents the decline of pulmonary function and acute asthma exacerbations after abrupt withdrawal of inhaled glucocorticoids.
    Altrakincept
  • HY-156196
    BI 894416 1810059-82-5
    BI 894416 is a spleen tyrosine kinase (SYK) inhibitor. BI 894416 has a deuterium-labeled derivative that can be used as an internal standard for bioanalytical studies. BI 894416 is applicable to the research of severe asthma.
    BI 894416